Key terms
About SCYX
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SCYX news
Apr 02
7:02am ET
Scynexis price target lowered to $6 from $7 at Guggenheim
Apr 02
6:46am ET
Buy Rating Affirmed for SCYNEXIS on Ibrexafungerp Success and Strong GSK Partnership
Mar 28
4:08pm ET
Scynexis reports FY23 EPS $1.39, consensus $1.42
Jan 31
7:05am ET
Promising Antifungal Drug Developments Bolster Buy Rating for SCYNEXIS
Jan 29
5:23pm ET
Scynexis announces presentation of data from fungerp candidate SCY-247
Jan 05
8:31am ET
Scynexis to present preclinical data on SCY-247
No recent news articles are available for SCYX
SCYX Financials
Key terms
Ad Feedback
SCYX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SCYX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
